SB 01683

Drug Profile

SB 01683

Alternative Names: SB-01683

Latest Information Update: 13 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sprint Bioscience
  • Class Antineoplastics
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Breast cancer

Highest Development Phases

  • Preclinical Breast cancer

Most Recent Events

  • 10 Jul 2018 Sprint Bioscience has patent protection for biomarkers to measure the effect of Vps34 inhibitors
  • 08 Aug 2016 SB 01683 is available for licensing as of 08 Aug 2016. http://www.sprintbioscience.com/
  • 08 Aug 2016 Preclinical trials in Breast cancer in Sweden (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top